Furthermore, mutations in transcription factors such as RUNX1 and IKAROS Family Zinc Finger 1 (IKZF1), as well as in epigenetic regulators including ASXL Transcriptional Regulator 1 (ASXL1), Splicing Factor 3b Subunit 1 (SF3B1), and U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1), are observed in more than 20% of patients with inv(3)/t(3;3) AML [24,30,31]. The gene discussed is ASXL1; the disease is acute myeloid leukemia.